Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial
Catherine S Diefenbach1, Fangxin Hong2, Richard F Ambinder3, Jonathon B Cohen4, Michael J Robertson5, Kevin A David6, Ranjana H Advani7, Timothy S Fenske8, Stefan K Barta9,10, Neil D Palmisiano11, Jakub Svoboda10, David S Morgan12, Reem Karmali13, Elad Sharon14, Howard Streicher14, Brad S Kahl15, Stephen M Ansell16
1Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
2Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Biostatistics Center, Dana Farber Cancer Institute, Boston, MA, USA
3Department of Oncology, Johns Hopkins University, Baltimore, MD USA
4Winship Cancer Institute, Emory University, Atlanta, GA, USA
5School of Medicine, Indiana University, Bloomington, IN, USA
6Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Jersey, NJ, USA
7Oncology Division, Stanford Cancer Institute, Stanford, CA, USA
8Division of Hematology and Oncology, Froedtert and the Medical College of Wisconsin, Wauwatosa, WI, USA
9Divison of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
10Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA
11Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
12Vanderbilt University Medical Center, Nashville, TN, USA
13Robert H Lurie Comprehensive Cancer Center, Northwestern University, Evanston, IL, USA
14Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethseda, MD, USA
15School of Medicine, Washington University, St Louis, MO, USA
16Division of Hematology, Mayo Clinic, Rochester, MN, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Haematology
Tập 7
e660-e670
Thông tin tác giả